title: Drug discovery strategies to outer membrane targets in Gram-negative pathogens.
abstract: This review will cover selected recent examples of drug discovery strategies which target the outer membrane (OM) of Gram-negative bacteria either by disruption of outer membrane function or by inhibition of essential gene products necessary for outer membrane assembly. Significant advances in pathway elucidation, structural biology and molecular inhibitor designs have created new opportunities for drug discovery within this target-class space.
authors.affiliation: AstraZeneca Neurosciences, Innovative Medicines and Early Development Unit, 141 Portland St., 10th Floor, Cambridge, MA 02139, USA. Electronic address: Dean.brown@astrazeneca.com.
authors.forename: Dean G
authors.initials: DG
authors.lastname: Brown
mesh_terms: D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D001425:Bacterial Outer Membrane Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D055808:Drug Discovery; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000378:metabolism; D008826:Microbial Sensitivity Tests
chemical_list: D000900:Anti-Bacterial Agents; D001425:Bacterial Outer Membrane Proteins
keywords: Antibacterial; Gram-negative; Lipid A; Lipopolysaccharide; Outer membrane